drugset / Trial / NCT06223308
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
NaSequentialOpen-labelTreatment
Summary
It is a phase I/II open label, multicenter study to assess the safety, tolerability, pharmacokinetics, and efficacy of HB0028 in patients with advanced solid tumors.
Timeline
- Start
- 2022-09-09
- Primary completion
- 2024-05-01
- Completion
- 2024-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HB0028 | Protein / enzyme biologic | — | Intravenous |